Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
23.4 ^USD	-1.10%		+1.83%	-21.92%

May. 10	UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating	MT
May. 10	Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise	MT

Rocket Pharmaceuticals, Inc. Announces Resignation of Carlos Garcia-Parada as Chief Financial Officer

March 11, 2022 at 04:05 pm EST

On March 10, 2022, Rocket Pharmaceuticals, Inc. announced that Carlos Garcia-Parada tendered his resignation as Chief Financial Officer of the Company, effective March 16, 2022, due to personal reasons. Mr. Garcia-Paradawill continue to serve as an advisor to the Company until March 31, 2022.

Latest news about Rocket Pharmaceuticals, Inc.

UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating	May. 10	MT
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise	May. 10	MT
Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy	May. 10	CI
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11	MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	Apr. 02	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	Apr. 02	MT
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	Apr. 02	CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	Mar. 26	MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	Mar. 26	CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	Mar. 26	CI
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating	Mar. 01	MT
Rocket Pharmaceuticals Q4 Loss Narrows	Feb. 26	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 25	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	Feb. 13	MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi	Feb. 13	DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	Feb. 13	CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM	Jan. 08
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director	Dec. 12	CI

Chart Rocket Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-13 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.4 USD

Average target price

50.08 USD

Spread / Average Target

+114.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ROCKET PHARMACEUTICALS, INC.	-21.92%	2.15B
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs